Latest From Nanobiotix SA
Nanobiotix’s CEO outlines to Scrip how the biotech plans to develop and expand its lead asset into multiple cancer indications, and create a blockbuster.
Three separate agreements team the innovative cancer research center with Takeda, Artios/ShangPharma, and Ziopharm. Hoth continues busy deal-making year by licensing gene therapy from North Carolina State.
Laurent Levy tells Scrip Nanobiotix’s freshly-created subsidiary Curadigm aims to improve bioavailability of nanomedicines by reducing liver and spleen toxicity and accumulation.
The CE mark will make Hensify nanoparticle radioenhancers available in 27 European countries. Hensify is the brand name for NBTXR3, an aqueous suspension of crystalline hafnium oxide nanoparticles, approved specifically for treating locally advanced soft-tissue sarcoma.
- Nanotechnology, Chips, etc.
- Drug Delivery
- Therapeutic Areas
- Western Europe
- Parent & Subsidiaries
- Nanobiotix SA
- Senior Management
Patrick Tricoli, PharmD, CEO & Global Head, Bus. Dev.
Philippe Mauberna, CFO
Edwina Baskin-Bey, MD, CMO
Brandon Owens, VP, Strategic Mktg. & Corp. Communications
- Contact Info
Phone: (33) 1 40 26 04 70
60 rue de Wattignies
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.